Actively Recruiting
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Led by PeproMene Bio, Inc. · Updated on 2025-11-20
36
Participants Needed
6
Research Sites
313 weeks
Total Duration
On this page
Sponsors
P
PeproMene Bio, Inc.
Lead Sponsor
C
City of Hope Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
CONDITIONS
Official Title
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent by the participant or legally authorized representative
- Age 18 years or older
- ECOG performance status of 2 or less
- Histologically confirmed B-cell Non-Hodgkin's Lymphoma including LBCL, MCL, and FL/MZL subtypes with prior treatment conditions
- BAFFR expression present on lymphoma cells
- Measurable disease with tumor size 1.5 cm or larger on imaging or disease evidence in blood, bone marrow, gastrointestinal tract, skin, or spleen
- Prior CAR T-cell therapy allowed if at least 3 months since last treatment and CD19 CAR-T cells are less than 5% before leukapheresis
- Adequate organ function including specified blood counts, liver and kidney function, heart and lung function
- Negative for HIV, active hepatitis B or C infection (or undetectable viral load if positive)
- Negative pregnancy test for females of childbearing potential
- Use of effective contraception or abstinence through 3 months after treatment
You will not qualify if you...
- Prior allogeneic stem cell transplant
- Autologous stem cell transplant within 6 months before leukapheresis
- Concurrent use of systemic steroids or chronic immunosuppressants
- Cardiac lymphoma involvement
- Need for urgent therapy due to tumor-related complications such as bowel obstruction
- Active autoimmune disease requiring immunosuppressants
- Primary immunodeficiency
- Significant cardiac conditions including severe heart failure, arrhythmia, recent heart attack or stroke within 6 months, or severe blood clots
- Neurologic conditions such as prior optic neuritis, central nervous system inflammatory diseases, or seizure disorders
- History of other malignancies unless removed or treated with curative intent and in remission for 3 years or more
- Uncontrolled infections or active central nervous system lymphoma
- Females who are pregnant or breastfeeding
- Investigator-determined safety concerns or potential noncompliance with study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
City of Hope Medical Center
Duarte, California, United States, 91010
Actively Recruiting
2
Stanford University
Stanford, California, United States, 94305
Actively Recruiting
3
University of Kansas Hospital
Kansas City, Kansas, United States, 66160
Actively Recruiting
4
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
5
Atrium Health Levine Cancer Institute - Morehead
Charlotte, North Carolina, United States, 28204
Actively Recruiting
6
Providence Swedish Cancer Institute
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
H
Hazel (Ting-Ying) Cheng, PhD
CONTACT
D
DeShaun Noakes, M.S.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here